The role of bevacizumab in the treatment of glioblastoma

Roberto Jose Diaz, Sheikh Ali, Mehreen Gull Qadir, Macarena I De La Fuente, Michael E. Ivan, Ricardo J Komotar

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Bevacizumab has been used in patients with GBM as a salvage therapy since its approval in the United States for recurrent GBM in 2009. In order to review the therapeutic effect of bevacizumab in the primary and recurrent clinical setting we have performed a systematic analysis of data from the published literature. Weighted median progression free survival and overall survival were calculated and compared to standard therapy or other experimental therapies. A qualitative analysis of the limited studies on health related quality of life and effects on steroid requirements was also undertaken. We found that the available literature supports the use of bevacizumab for prolonging PFS and OS in the recurrent setting either alone or in combination with a cytotoxic agent (P < 0.05), but does not support its use in the primary setting (P > 0.05). The survival advantage of bevacizumab compared to experimental therapy at recurrence is limited to 4 months. There is no additional benefit reported to date in health-related quality of life with the use of bevacizumab, although it may reduce steroid requirements. On average there is one side-effect event per patient and 74% of these events are grade 3 toxicity or higher. Further studies investigating the role of bevacizumab in combination with cytotoxic agents at recurrence are awaited.

Original languageEnglish (US)
Pages (from-to)1-13
Number of pages13
JournalJournal of Neuro-Oncology
DOIs
StateAccepted/In press - May 19 2017

Fingerprint

Glioblastoma
Investigational Therapies
Cytotoxins
Therapeutics
Steroids
Quality of Life
Recurrence
Salvage Therapy
Survival
Therapeutic Uses
Disease-Free Survival
Bevacizumab

Keywords

  • Avastin
  • Bevacizumab
  • Chemotherapy
  • Glioblastoma
  • Survival
  • VEGF

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Cite this

The role of bevacizumab in the treatment of glioblastoma. / Diaz, Roberto Jose; Ali, Sheikh; Qadir, Mehreen Gull; De La Fuente, Macarena I; Ivan, Michael E.; Komotar, Ricardo J.

In: Journal of Neuro-Oncology, 19.05.2017, p. 1-13.

Research output: Contribution to journalArticle

Diaz, Roberto Jose ; Ali, Sheikh ; Qadir, Mehreen Gull ; De La Fuente, Macarena I ; Ivan, Michael E. ; Komotar, Ricardo J. / The role of bevacizumab in the treatment of glioblastoma. In: Journal of Neuro-Oncology. 2017 ; pp. 1-13.
@article{5377e41d59a94792a24f16c4967301ca,
title = "The role of bevacizumab in the treatment of glioblastoma",
abstract = "Bevacizumab has been used in patients with GBM as a salvage therapy since its approval in the United States for recurrent GBM in 2009. In order to review the therapeutic effect of bevacizumab in the primary and recurrent clinical setting we have performed a systematic analysis of data from the published literature. Weighted median progression free survival and overall survival were calculated and compared to standard therapy or other experimental therapies. A qualitative analysis of the limited studies on health related quality of life and effects on steroid requirements was also undertaken. We found that the available literature supports the use of bevacizumab for prolonging PFS and OS in the recurrent setting either alone or in combination with a cytotoxic agent (P < 0.05), but does not support its use in the primary setting (P > 0.05). The survival advantage of bevacizumab compared to experimental therapy at recurrence is limited to 4 months. There is no additional benefit reported to date in health-related quality of life with the use of bevacizumab, although it may reduce steroid requirements. On average there is one side-effect event per patient and 74{\%} of these events are grade 3 toxicity or higher. Further studies investigating the role of bevacizumab in combination with cytotoxic agents at recurrence are awaited.",
keywords = "Avastin, Bevacizumab, Chemotherapy, Glioblastoma, Survival, VEGF",
author = "Diaz, {Roberto Jose} and Sheikh Ali and Qadir, {Mehreen Gull} and {De La Fuente}, {Macarena I} and Ivan, {Michael E.} and Komotar, {Ricardo J}",
year = "2017",
month = "5",
day = "19",
doi = "10.1007/s11060-017-2477-x",
language = "English (US)",
pages = "1--13",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",

}

TY - JOUR

T1 - The role of bevacizumab in the treatment of glioblastoma

AU - Diaz, Roberto Jose

AU - Ali, Sheikh

AU - Qadir, Mehreen Gull

AU - De La Fuente, Macarena I

AU - Ivan, Michael E.

AU - Komotar, Ricardo J

PY - 2017/5/19

Y1 - 2017/5/19

N2 - Bevacizumab has been used in patients with GBM as a salvage therapy since its approval in the United States for recurrent GBM in 2009. In order to review the therapeutic effect of bevacizumab in the primary and recurrent clinical setting we have performed a systematic analysis of data from the published literature. Weighted median progression free survival and overall survival were calculated and compared to standard therapy or other experimental therapies. A qualitative analysis of the limited studies on health related quality of life and effects on steroid requirements was also undertaken. We found that the available literature supports the use of bevacizumab for prolonging PFS and OS in the recurrent setting either alone or in combination with a cytotoxic agent (P < 0.05), but does not support its use in the primary setting (P > 0.05). The survival advantage of bevacizumab compared to experimental therapy at recurrence is limited to 4 months. There is no additional benefit reported to date in health-related quality of life with the use of bevacizumab, although it may reduce steroid requirements. On average there is one side-effect event per patient and 74% of these events are grade 3 toxicity or higher. Further studies investigating the role of bevacizumab in combination with cytotoxic agents at recurrence are awaited.

AB - Bevacizumab has been used in patients with GBM as a salvage therapy since its approval in the United States for recurrent GBM in 2009. In order to review the therapeutic effect of bevacizumab in the primary and recurrent clinical setting we have performed a systematic analysis of data from the published literature. Weighted median progression free survival and overall survival were calculated and compared to standard therapy or other experimental therapies. A qualitative analysis of the limited studies on health related quality of life and effects on steroid requirements was also undertaken. We found that the available literature supports the use of bevacizumab for prolonging PFS and OS in the recurrent setting either alone or in combination with a cytotoxic agent (P < 0.05), but does not support its use in the primary setting (P > 0.05). The survival advantage of bevacizumab compared to experimental therapy at recurrence is limited to 4 months. There is no additional benefit reported to date in health-related quality of life with the use of bevacizumab, although it may reduce steroid requirements. On average there is one side-effect event per patient and 74% of these events are grade 3 toxicity or higher. Further studies investigating the role of bevacizumab in combination with cytotoxic agents at recurrence are awaited.

KW - Avastin

KW - Bevacizumab

KW - Chemotherapy

KW - Glioblastoma

KW - Survival

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=85019638822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019638822&partnerID=8YFLogxK

U2 - 10.1007/s11060-017-2477-x

DO - 10.1007/s11060-017-2477-x

M3 - Article

SP - 1

EP - 13

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

ER -